Comment
doi: 10.1001/jamahealthforum.2022.0189.
The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid-Building an Evidence Base
Affiliations
- PMID: 36219020
- DOI: 10.1001/jamahealthforum.2022.0189
Item in Clipboard
Comment
The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid-Building an Evidence Base
JAMA Health Forum.
.
Free article
No abstract available
Comment on
-
Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.JAMA Health Forum. 2022 Jun 24;3(6):e221757. doi: 10.1001/jamahealthforum.2022.1757. eCollection 2022 Jun. JAMA Health Forum. 2022. PMID: 35977240 Free PMC article.
Similar articles
-
Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.Health Aff (Millwood). 2024 Jan;43(1):55-63. doi: 10.1377/hlthaff.2023.00288. Health Aff (Millwood). 2024. PMID: 38190595 Free PMC article.
-
Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.JAMA Health Forum. 2022 Jun 24;3(6):e221757. doi: 10.1001/jamahealthforum.2022.1757. eCollection 2022 Jun. JAMA Health Forum. 2022. PMID: 35977240 Free PMC article.
-
Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans.JAMA. 2019 Jul 9;322(2):166-167. doi: 10.1001/jama.2019.6581. JAMA. 2019. PMID: 31287514 Free PMC article.
-
How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.Addict Sci Clin Pract. 2020 Jun 29;15(1):20. doi: 10.1186/s13722-020-00194-7. Addict Sci Clin Pract. 2020. PMID: 32600402 Free PMC article. Review.
-
Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good?JAMA Intern Med. 2013 Sep 23;173(17):1571-2. doi: 10.1001/jamainternmed.2013.9059. JAMA Intern Med. 2013. PMID: 23877740 Review. No abstract available.
Cited by
-
Changes in Medicaid Fee-for-Service Benefit Design for Substance Use Disorder Treatment During the Opioid Crisis, 2014 to 2021.JAMA Health Forum. 2023 Aug 4;4(8):e232502. doi: 10.1001/jamahealthforum.2023.2502. JAMA Health Forum. 2023. PMID: 37566428 Free PMC article.
-
US payment policy for medications to treat opioid use disorder: landscape and opportunities.Health Aff Sch. 2024 Feb 27;2(3):qxae024. doi: 10.1093/haschl/qxae024. eCollection 2024 Mar. Health Aff Sch. 2024. PMID: 38756918 Free PMC article.
-
Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.JAMA Health Forum. 2022 Nov 4;3(11):e224001. doi: 10.1001/jamahealthforum.2022.4001. JAMA Health Forum. 2022. PMID: 36331441 Free PMC article.
-
Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.JAMA Netw Open. 2023 May 1;6(5):e2312030. doi: 10.1001/jamanetworkopen.2023.12030. JAMA Netw Open. 2023. PMID: 37145594 Free PMC article.
-
Medicaid managed care restrictions on medications for the treatment of opioid use disorder.Health Serv Res. 2025 Apr;60 Suppl 2(Suppl 2):e14394. doi: 10.1111/1475-6773.14394. Epub 2024 Oct 10. Health Serv Res. 2025. PMID: 39390740 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
